ORIGINAL PAPER
Profiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association?
More details
Hide details
1
Department of Medicine, Lagos State University College of Medicine (LASUCOM), Ikeja, Nigeria
2
Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Nigeria
3
Department of Hematology, Alimosho General Hospital, Ikeja, Nigeria
4
Department of Medicine, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria
5
Department of General Medicine, Reliance Medical Clinics, Abuja, Nigeria
Submission date: 2024-06-24
Final revision date: 2024-10-12
Acceptance date: 2024-10-29
Publication date: 2024-12-24
Corresponding author
Gbenga Joshua Odunlami
Department of Medicine, Obafemi Awolowo University, OAUTHC, PMB 5538, Ile-Ife, Osun State, Nigeria, 220212
Reumatologia 2024;62(6):430-438
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Systemic lupus erythematosus (SLE) and sickle cell disease (SCD) are distinct multisystemic diseases that commonly affect blacks. There are few reports of their co-existence in Western literature and a paucity of reports in Sub-Saharan Africa. Their co-existence is associated with diagnostic delay and treatment dilemmas. The aim is to describe the clinical, laboratory, and treatment profile of Nigerian lupus with sickle cell disease.
Material and methods:
A 7-year retrospective descriptive study of lupus patients with sickle cell disease was performed. Medical records of eligible patients were extracted into a proforma, transferred into SPSS, and analyzed with descriptive statistics. Sociodemographic, clinical, laboratory, and treatment data were presented as frequency and percentages.
Results:
Twelve SLE-SCD cases (female 11, male 1) were identified. The mean age was 28.5 years and the mean duration of illness prior to diagnosis was 9.5 years. The median follow-up period was 3.1 years and the common presentations were mucocutaneous (66%), renal, (50%) serositis (33%), and neurological (16%) in decreasing order. All had anemia and positive antinuclear antibody, 33% had pancytopenia and 75% had positive anti-dsDNA and anti-Smith. Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis.
Conclusions:
Sickle cell disease and SLE should be considered in SCD with atypical clinical and laboratory features. We hope this report will raise diagnostic suspicion and prompt early diagnosis and treatment to prevent multiorgan damage that may ensue from such an association.
REFERENCES (35)
1.
Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol 2023; 10: e585–e599, DOI: 10.1016/S2352-3026(23)00118-7.
2.
Gill TK, Mittinty MM, March LM, et al. Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 2023; 5: e670–e682, DOI: 10.1016/S2665-9913(23)00232-1.
3.
Tebbi CK. Sickle Cell Disease, a Review. Hematol 2022; 3: 341–366, DOI: 10.3390/hemato3020024.
4.
Jia X, Tan L, Chen S, et al. Monogenic lupus: Tracing the therapeutic implications from single gene mutations. Clin Immunol 2023; 254: 109699, DOI: 10.1016/j.clim.2023.109699.
5.
Schilirò D, Silvagni E, Ciribè B, et al. Systemic lupus erythematosus: one year in review 2024. Clin Exp Rheumatol 2024; 42: 583–592, DOI: 10.55563/clinexprheumatol/mnvmvo.
6.
Fatoye, F., Gebrye, T. & Mbada, C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle-income countries: a systematic review and meta-analysis. Rheumatol Int 2022; 42: 2097–2107, DOI: 10.1007/s00296-022-05183-4.
7.
Essouma M, Nkeck JR, Endomba FT, et al. Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. J Autoimmun 2020; 106: 102348, DOI: 10.1016/j.jaut.2019.102348.
8.
Osaze O, Olaosebikan HB, Yerima A, et al. Pattern of systemic lupus erythematosus in NIGERIA: a multicentre descriptive hospital-based study. Clin Rheumatol 2023; 42: 2787–2797, DOI: 10.1007/s10067-023-06672-y.
9.
Kronzer VL, Bridges SL Jr, Davis JM 3rd. Why women have more autoimmune diseases than men: An evolutionary perspective. Evol Appl 2020; 14: 629–633, DOI: 10.1111/eva.13167.
10.
Sawlani A, Masood R, Kumar J, Saahil K. Coexistence of Sickle Cell Thalassaemia with Overlapping Syndrome: A Case Report of Systemic Lupus Erythematosus and Autoimmune Hepatitis. European Medical Journal 2024; DOI: 10.33590/emj/11000015.
11.
Li-Thiao-Te V, Uettwiller F, Quartier P, et al. Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges. Pediatr Rheumatol Online J 2018; 16: 5, DOI: 10.1186/s12969-017-0221-x.
12.
Michel M, Habibi A, Godeau B, et al. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases. Semin Arthritis Rheum 2008; 38: 228–240, DOI: 10.1016/j.semarthrit.2007.10.003.
13.
Christiaens C, Florkin B, Philippet P. Co-existence d’une drépanocytose et d’un lupus érythémateux disséminé [Coexistence of sickle cell disease and systemic lupus erythematosus]. Rev Med Liege 2020; 75: 115–120 [Article in French].
14.
Robazzi TC, Alves C, Abreu L, Lemos G. Coexistência de lúpus eritematoso sistêmico e doença falciforme: relato de caso e revisão da literatura [Coexisting systemic lupus erythematosus and sickle cell disease: case report and literature review]. Rev Bras Reumatol 2015; 55: 68–74, DOI: 10.1016/j.rbr.2013.05.005 [Article in Portuguese].
15.
Mausoléo A, Fredeau L, Chrétien P, et al. Autoimmunity in sickle cell disease: Analysis of a large cohort of adult patients. Am J Hematol 2023; 98: E315–E317, DOI: 10.1002/ajh.27061.
16.
Aboderin FI, Oduola T, Davison GM, Oguntibeju OO. A Review of the Relationship between the Immune Response, Inflammation, Oxidative Stress, and the Pathogenesis of Sickle Cell Anaemia. Biomedicines 2023; 11: 2413, DOI: 10.3390/biomedicines11092413.
17.
De Azevedo JTC, Malmegrim KCR. Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett 2020; 224: 1–11, DOI: 10.1016/j.imlet.2020.04.012.
18.
Piccin A, O’Connor-Byrne N, Daves M, et al. Autoimmune disease and sickle cell anemia: ‘Intersecting pathways and differential diagnosis’. Br J Haematol 2022; 197: 518–528, DOI: 10.1111/bjh.18109.
19.
Boulassel MR, Al-Naamani A, Al-Zubaidi A, et al. Coexistence of sickle cell disease and systemic lupus erythematosus is associated with quantitative and qualitative impairments in circulating regulatory B cells. Hum Immunol 2022; 83: 818–825, DOI: 10.1016/j.humimm.2022.09.005.
20.
Adigwe OP, Onavbavba G, Onoja SO. Impact of Sickle Cell Disease on Affected Individuals in Nigeria: A Critical Review. Int J Gen Med 2023; 16: 3503–3515, DOI: 10.2147/IJGM.S410015.
21.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725, DOI: 10.1002/art.1780400928.
22.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686, DOI: 10.1002/art.34473.
23.
Aringer M, Costenbader K, Daikh D, et al. European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412, DOI: 10.1002/art.40930.
24.
Wilson FM, Clifford GO, Wolf PL. Lupus erythematosus associated with sickle cell anemia. Arthritis Rheum 1964; 7: 443–449. DOI: 10.1002/art.1780070411.
25.
Faleye AD, Akinola IJ, Olaosebikan BH, et al. Coexisting sickle cell disease and autoimmune diseases among Nigerian children. Rheumatology 2023; 62: kead323.034, DOI: 10.1093/rheumatology/kead323.034.
26.
Motta I, Giannotta J, Ferraresi M, et al. Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature. J Clin Med 2021; 10: 3439, DOI: 10.3390/jcm10153439.
27.
Damanhouri GA, Jarullah J, Marouf S, et al. Clinical biomarkers in sickle cell disease. Saudi J Biol Sci 2015; 22: 24–31, DOI: 10.1016/j.sjbs.2014.09.005.
28.
Karlsson J, Wetterö J, Weiner M, et al. Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity. Arthritis Res Ther 2022; 24: 139, DOI: 10.1186/s13075-022-02831-9.
29.
Toly-Ndour C, Rouquette AM, Obadia S, et al. High titers of autoantibodies in patients with sickle-cell disease. J Rheumatol 2011; 38: 302–309, DOI: 10.3899/jrheum.100667.
30.
Merashli M, Arcaro A, Graf M, et al. Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis. Clin Appl Thromb Hemost 2021; 27: 10760296211002914, DOI: 10.1177/10760296211002914.
31.
Truffinet F, Compain C, Manea ME, et al. Antinuclear and Specific Autoantibodies Predict Autoimmune Disease in Sickle Cell Patients: A Longitudinal Cohort Study. Blood 2023; 142: 3859, DOI: 10.1182/blood-2023-177569.
32.
Scarpato B, Strykowski R, Lawrence R, et al. Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease. Thrombosis Update 2022; 6: 100101, DOI: 10.1016/j.tru.2022.100101.
33.
Bello N, Meyers KJ, Workman J, et al. Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus. Rheumatol Ther 2023; 10: 7–34, DOI: 10.1007/s40744-022-00513-1.
34.
Zeppieri J, Aroke D, Cohen AJ. Impact of Autoimmune Disease and Its Treatment on Adults with Sickle Cell Disease. Blood 2021; 138: 4182–4182, DOI: 10.1182/blood-2021-153233.
35.
Nawaiseh M, Roto A, Nawaiseh Y, et al. Risk factors associated with sickle cell retinopathy: findings from the Cooperative Study of Sickle Cell Disease. Int J Retin Vitr 2022; 8: 68, DOI: 10.1186/s40942-022-00419-8.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.